Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297Product type:GuidanceProgramme:Technology appraisal guidanceExpected publication date: 28 July 2021
Suspected cancer: recognition and referral (NG12)Product type:GuidanceProgramme:NICE guidelineLast updated: 12 January 2026Published: 23 June 2015
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA1119)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 January 2026
Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (TA1116)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 December 2025
Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1114)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 December 2025
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma (TA1113)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 December 2025
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable (TA1098)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 September 2025
Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 treatments (terminated appraisal) (TA1084)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 July 2025
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment when a stem cell transplant is unsuitable (terminated appraisal) (TA1083)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 July 2025
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma (TA1081)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 July 2025
Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma (TA1059)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 May 2025
Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over (TA1054)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 April 2025
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia (TA1049)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 March 2025
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable (TA1048)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 March 2025
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1023)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 December 2024
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA1018)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 November 2024
Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1015)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 November 2024
Avapritinib for treating advanced systemic mastocytosis (TA1012)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 November 2024
Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia (TA1013)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 October 2024
Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment (TA1001)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 4 September 2024
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal) (TA987)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 July 2024
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation (TA979)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 June 2024
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal) (TA978)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 May 2024
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under (TA975)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 May 2024
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (TA974)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 May 2024
Selinexor with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatments (TA970)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 May 2024
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over (TA967)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 May 2024
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 May 2024Published: 3 September 2018
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA968)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 April 2024
Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 March 2024
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA954)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 March 2024
Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over (TA949)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 February 2024
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments (TA947)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 January 2024
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal) (TA936)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 November 2023
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal) (TA933)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 November 2023
Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal) (TA932)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 November 2023
Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 November 2023
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable (TA917)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 October 2023
Ruxolitinib for treating polycythaemia vera (TA921)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 October 2023
Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA927)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 October 2023
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy (TA895)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 June 2023
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma (TA894)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 June 2023
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over (TA893)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 June 2023
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA897)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 June 2023
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia (TA891)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 May 2023
Mosunetuzumab for treating relapsed or refractory follicular lymphoma (TA892)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 May 2023
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA889)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 May 2023
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma (TA883)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 May 2023
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma (TA874)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 March 2023
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (TA872)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 February 2023
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA870)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 February 2023
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA841)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 November 2022
Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal) (TA842)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 November 2022
Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids (terminated appraisal) (TA840)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 November 2022
Zanubrutinib for treating Waldenstrom’s macroglobulinaemia (TA833)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 October 2022
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy (TA827)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 October 2022
Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal) (TA822)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 September 2022
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 August 2022
Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal) (TA811)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 July 2022
Venetoclax for treating chronic lymphocytic leukaemia (TA796)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 June 2022
Ibrutinib for treating Waldenstrom’s macroglobulinaemia (TA795)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 June 2022
Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA787)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 April 2022
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 April 2022
Freelite assays for diagnosing multiple myeloma and related conditions (terminated assessment) (HTG619)Product type:GuidanceProgramme:HealthTech guidancePublished: 30 March 2022
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal) (TA782)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 March 2022
Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal) (TA774)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 March 2022
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies (TA772)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 February 2022
Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal) (TA771)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 February 2022
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 February 2022
Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA765)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 February 2022
Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome (TA754)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 December 2021
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA726)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 September 2021
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA727)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 September 2021
Midostaurin for treating advanced systemic mastocytosis (TA728)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 September 2021
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 August 2021
Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal) (TA717)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 July 2021
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) (TA714)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 July 2021
Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal) (TA702)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 May 2021
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal) (TA703)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 May 2021
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (TA695)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 April 2021
Acalabrutinib for treating chronic lymphocytic leukaemia (TA689)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 April 2021
Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) (TA686)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 March 2021
Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma (TA680)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 March 2021
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma (TA677)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 February 2021
Carfilzomib for previously treated multiple myeloma (TA657)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 November 2020
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma (TA658)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 November 2020
Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma (TA649)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 September 2020
Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal) (TA646)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 September 2020
Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (TA641)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 August 2020
Gilteritinib for treating relapsed or refractory acute myeloid leukaemia (TA642)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 August 2020
Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 August 2020
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal) (TA634)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 June 2020
Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 May 2020
Lenalidomide with rituximab for previously treated follicular lymphoma (TA627)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 April 2020
Ibrutinib with rituximab for treating Waldenstrom’s macroglobulinaemia (terminated appraisal) (TA608)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 October 2019
Idelalisib for treating refractory follicular lymphoma (TA604)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 October 2019
Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal) (TA603)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 September 2019
Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA602)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 September 2019
Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity (TA589)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 July 2019
Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies (TA171)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 26 June 2019Published: 18 June 2009
Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 26 June 2019Published: 24 September 2014
Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 June 2019
Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 June 2019
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 April 2019
Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) (TA576)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 April 2019
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 February 2019
Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia (TA552)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 December 2018
Decitabine for untreated acute myeloid leukaemia (terminated appraisal) (TA548)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 December 2018
Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal) (TA549)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 December 2018
Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (TA545)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 November 2018
Myeloma: diagnosis and management (NG35)Product type:GuidanceProgramme:NICE guidelineLast updated: 25 October 2018Published: 10 February 2016
Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia (TA541)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 September 2018
Arsenic trioxide for treating acute promyelocytic leukaemia (TA526)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 June 2018
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA524)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 June 2018
Midostaurin for untreated acute myeloid leukaemia (TA523)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 June 2018
Obinutuzumab for untreated advanced follicular lymphoma (TA513)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 March 2018
Ibrutinib for treating relapsed or refractory mantle cell lymphoma (TA502)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 January 2018
Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (TA478)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 4 October 2017
Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) (TA469)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 August 2017
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 July 2017
Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) (TA453)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 July 2017
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA454)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 July 2017
Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) (TA452)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 July 2017
Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia (TA450)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 June 2017
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 June 2017
Elotuzumab for previously treated multiple myeloma (terminated appraisal) (TA434)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 March 2017
Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal) (TA437)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 March 2017
Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (TA429)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 January 2017
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 January 2017
Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 December 2016
Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 December 2016
Pegaspargase for treating acute lymphoblastic leukaemia (TA408)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 September 2016
Bosutinib for previously treated chronic myeloid leukaemia (TA401)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 August 2016
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts (TA399)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 July 2016
Non-Hodgkin’s lymphoma: diagnosis and management (NG52)Product type:GuidanceProgramme:NICE guidelinePublished: 20 July 2016
Haematological cancers: improving outcomes (NG47)Product type:GuidanceProgramme:NICE guidelinePublished: 25 May 2016
Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 March 2016
Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 January 2016
Guidance on the use of imatinib for chronic myeloid leukaemia (TA70)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 21 January 2016Published: 22 October 2003
Bortezomib for previously untreated mantle cell lymphoma (TA370)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 December 2015
Idelalisib for treating chronic lymphocytic leukaemia (TA359)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 October 2015
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 June 2015
Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation (TA311)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 April 2014
Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma (TA306)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 February 2014
Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal) (TA270)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 December 2012
Rituximab for the first-line treatment of stage III-IV follicular lymphoma (TA243)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 January 2012
Mifamurtide for the treatment of osteosarcoma (TA235)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 October 2011
Bortezomib and thalidomide for the first‑line treatment of multiple myeloma (TA228)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 July 2011
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma (TA226)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 June 2011
Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia (TA218)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 March 2011
Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (TA216)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 February 2011
Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal) (TA206)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 October 2010
Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal) (TA207)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 October 2010
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 July 2010
Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 July 2009
Rituximab for the treatment of relapsed or refractory stage 3 or 4 follicular non-Hodgkin's lymphoma (TA137)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 February 2008
Bortezomib monotherapy for relapsed multiple myeloma (TA129)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 October 2007
Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia (TA119)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 February 2007
Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia (TA29)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 September 2001
clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia (MIB278)Product type:AdviceProgramme:Medtech innovation briefingPublished: 30 November 2021
MMprofiler for prognostic risk classification in multiple myeloma (MIB270)Product type:AdviceProgramme:Medtech innovation briefingPublished: 10 August 2021
The Arrow OnControl powered bone marrow biopsy system for bone marrow aspiration and biopsy (MIB19)Product type:AdviceProgramme:Medtech innovation briefingPublished: 12 February 2015
Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)Product type:AdviceProgramme:Evidence summaryPublished: 9 September 2014
Suspected cancer (QS124)Product type:Quality standardLast updated: 5 December 2017Published: 30 June 2016